| Previous Close | 100.64 |
| Open | 100.03 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 100.03 - 103.96 |
| 52 Week Range | 92.28 - 134.69 |
| Volume | 176,274 |
| Avg. Volume | 101,775 |
| Market Cap | 4.13B |
| Beta | 0.27 |
| PE Ratio (TTM) | 9.22 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Markit•5 days agoSee what the IHS Markit Score report has to say about Taro Pharmaceutical Industries Ltd.
Short interest is low for TARO with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on August 10. The net inflows of $1.59 billion over the last one-month into ETFs that hold TARO are not among the highest of the last year and have been slowing.
Markit•9 days agoIHS Markit Score upgrades Taro Pharmaceutical Industries Ltd to 71 out of 100, despite ranking positively in only one IHS Markit category.
Short interest is low for TARO with fewer than 5% of shares on loan. The net inflows of $1.28 billion over the last one-month into ETFs that hold TARO are not among the highest of the last year and have been slowing.
- Associated Press•10 days ago
Taro posts 1Q profit
On a per-share basis, the Haifa Bay, Israel-based company said it had net income of $1.35. The drug maker posted revenue of $161.3 million in the period. Taro shares have increased nearly 4 percent since ...
